"The "miracle weight loss drug" may be able to treat Alzheimer's disease, but clinical efficacy still needs to be verified."

Recently, a systematic review published in Molecular and Cellular Neuroscience linked Alzheimer's disease with the highly anticipated anti-diabetic and "weight loss wonder drug" - GLP-1 receptor agonists. Led by Anglia Ruskin University in the UK, the study found that various GLP-1 drugs including semaglutide and liraglutide can significantly reduce Alzheimer's disease pathology in the brain, demonstrating great potential for neuroprotection. The research team emphasizes the need to understand the potential and limitations of this new type of therapy simultaneously. Large-scale epidemiological studies have shown that for type 2 diabetes patients who start using GLP-1 drugs before dementia symptoms appear, their risk of developing Alzheimer's disease in the future is significantly reduced. This suggests that the true value of the "weight loss wonder drug" may lie in early intervention for Alzheimer's disease, but its actual effectiveness still requires more validation from larger experiments.